Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will ...
Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket ...
A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial ...
Biogen’s acquisition of Apellis highlights interest in complement-based ophthalmology and multi-indication platforms. NM5072 represents a broad multi-indication opportunity, supported by preclinical ...
RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, ...
Pixel 11 Pro's HiLight LED is heavily restricted in functionality, but the HiLight Studio app turns it into a proper ...
A comprehensive review is shedding new light on Fabry disease, a rare inherited disorder that can progressively damage multiple organs and significantly affect quality of life.
Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not ...
The platform combines modular agility, self-service provisioning, and automated management with complete data control and ...
Researchers at Peter Mac have discovered why breast cancer treatment stops working for some patients, uncovering the ...
Here are the 5 best weapons for Qingxiao in Wuthering Waves 3.6, including a 4 star option, and the top alternatives to her ...
Major update introduces 3D wireframe editing and enhances the mobile CAD experience for engineers, designers, contractors, and other professionals. SAN FRANCISCO, CA, UNITED STATES, August 20, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results